Full Report

Claude View

Know the Business

Genpact is a $5.1B people-and-process factory — 146,500 employees running the back-office plumbing of roughly a quarter of the Fortune Global 500. It was born inside GE, spun out in 2005, and still competes primarily on labor arbitrage dressed up as "process intelligence." The real investment question is not whether Genpact can win more business-process deals — it is whether the seats, which are the P&L, survive agentic AI. Management is loudly pivoting to AI ($1.2B "Advanced Technology Solutions" bucket, growing double digits), but 76% of revenue still comes from Core Business Services where AI is a customer-demanded productivity giveback, not a growth catalyst.

1. How This Business Actually Works

Genpact sells outcomes, but gets paid by the seat. Roughly 75% of its cost base is people — mostly India-based — and revenue lives and dies by billable headcount × utilization × bill rate. Contracts are long-dated (MSAs of 3–7 years, SOWs of 2–5), which creates recurring-revenue optics, but renewal is re-priced every few years and the client's in-house GCC option puts a ceiling on pricing power.

Three things actually drive incremental profit:

1. Pyramid steepness. Early in a contract, the supervisor-to-agent ratio is high and margins are thin. As processes stabilize, junior seats replace senior seats and margin expands — this is why management calls out "mix" every quarter.
2. Productivity give-back asymmetry. Most MSAs force Genpact to share productivity gains after year 1 or 2. If Genpact automates 20% of seats, clients often capture the majority. AI makes this lever both larger and scarier.
3. Revenue currency vs. cost currency. 75% of revenue is in USD; most costs are in INR, PHP, RON, MXN. A strong dollar boosts margin by 50–100 bps; a weak dollar compresses it. Genpact hedges, but imperfectly.

The three industry segments earn nearly identical adjusted margins (17–19%) — this is not an accident. Pricing is set by the labor pyramid and productivity commitments, not by vertical domain expertise. The "moat" Genpact claims in each industry is real on the sales side (it explains why it wins the deal) but does not translate into differentiated per-seat economics.

2. The Playing Field

Genpact sits in the awkward middle of IT services: too small to compete with Accenture's consulting-led model, too big and broad to be a pure-play BPM specialist like WNS. The peer table below is what actually matters.

What the peer set reveals:

• Accenture is the ceiling, not the competitor. ACN prints ~38% ROIC on a near-identical operating margin to Genpact (14.8% vs 14.8%) because its capital intensity is lower and its consulting deals rotate inventory faster. Genpact cannot get there — its model owns more delivery infrastructure and carries more receivables.
• EXLS is what "good" looks like for Genpact's scale tier. Similar model, half the employees, better growth (+13.6% CC in 2025 vs Genpact's +6.4%), higher ROIC, richer multiple. EXLS has leaned harder into analytics/AI and kept headcount growth below revenue growth (9.8% vs 13.6%) — textbook operating leverage.
• WNS is the fallen comp. Once the premium pure-play BPM, now growing ~2% with declining earnings. Capgemini's pending acquisition of WNS in 2025 signals that sub-scale standalone BPM is structurally challenged.
• Cognizant/Infosys are the India-heritage IT giants whose multiples pull Genpact's down. The market treats Genpact more like cheap IT services (11.7x P/E) than like a consulting/AI franchise.

Genpact trades closer to CTSH on multiples than to EXLS — the market is pricing it as a commoditized offshore labor arbitrage story, not an AI transformation play, despite management's messaging.

3. Is This Business Cyclical?

Yes, but the cycle hits differently than most IT services. Genpact's cycle is project pauses + pricing give-backs, not revenue cliffs. Managed-services contracts rarely terminate; they get paused, re-scoped downward, or forced into productivity concessions.

The FY2023 slowdown (+1% constant currency) is the most informative datapoint. Rising rates plus the 2023 regional-banking stress caused financial-services clients to defer discretionary work (Data-Tech-AI projects dropped sharply), while Digital Operations held steady. That is the cycle signature: advisory and project work is the first thing clients cut; managed seats are sticky because unwinding them is expensive. This is why Genpact's revenue is more resilient than, say, Accenture's consulting, but also why upside capture is muted when the cycle turns.

Secondary cycle exposures worth naming:

• FX. A 5% INR/USD move equals roughly 50–80 bps of operating margin. The INR sits at record lows vs USD in 2025, which has quietly helped margins.
• Wage inflation. India wage hikes run 8–10% annually. Genpact passes roughly half via pyramid re-design and half via re-pricing — meaning margins slowly compress unless automation absorbs the rest.
• Client GCC (in-house) decisions. When India-heritage enterprises decide to insource (large banks and retailers expanded GCCs 2023–2025), Genpact loses RFPs before they start. This is structural, not cyclical, but the decision cadence is lumpy.

4. The Metrics That Actually Matter

Skip gross margin. Skip headline revenue growth. These four metrics explain value creation in this business.

Genpact sits in the bottom third of its peer group on revenue per employee — by design, because it runs more managed-service seats than project work. The bull case requires this number to climb toward EXLS (~$46K) over 3–5 years. The bear case is that it stays flat: AI takes out seats and rates, net-neutral.

New bookings is the single most important leading indicator nobody puts enough weight on. Bookings were $5.7B in FY24 and $5.5B in FY25 — a 3% decline while revenue grew 6.6%. Either management is being more conservative in what it counts, or growth decelerates in FY26. Watch the Q1–Q2 FY26 prints closely.

5. What I'd Tell a Young Analyst

Five things to actually watch, in priority order:

1. New bookings trajectory. Not the absolute number — the direction. Two consecutive down years means structural, not lumpy.
2. Advanced Technology Solutions growth rate and mix. Management drew the line at 23.7% for FY25. If this is not 28%+ by FY27, the AI pivot is failing.
3. Revenue per employee. The cleanest test of whether AI is a net positive or a net giveback. If headcount grows faster than revenue for two years, the margin story breaks.
4. Top-20 client concentration (currently 34.4%). Stable or declining is fine. Rising concentration means new-logo wins are drying up.
5. Adjusted operating margin vs. management guidance. Genpact has a decade-long track record of hitting guidance within 50 bps. A miss here is a thesis-breaking event.

What the market is likely wrong about: the bear case on AI disintermediation is overstated in the near term (2026–2027) because Genpact's seats are buried inside regulated, domain-heavy workflows that LLMs cannot touch without human oversight. But the bull case on AI re-rating is also overstated — agentic solutions still decelerate as volumes compound, because clients capture most of the productivity gains on renewal. This is a mid-single-digit growth, mid-teens margin business trading at a mid-teens multiple. That is roughly fair. Do not own it for surprise; own it for dividend (~1.9%), buybacks (~3% of float annually), and optionality on the ATS mix shift. If you cannot articulate which KPI would make you sell, do not buy.

Claude View

The Numbers

Why does G trade here today? Genpact is being valued as a melting-ice-cube BPO ($6.2B market cap, ~12x trailing earnings, 1.4x EV/Sales, 8.3x EV/EBITDA) despite generating $725M of free cash flow, growing revenue 6.6% in FY25, and carrying a clean 0.9x net debt/EBITDA balance sheet. The market is paying for the 76% of revenue it calls "Core Business Services" (3.7% growth, structurally GenAI-exposed) and assigning almost zero premium for the 24% "Advanced Technology Solutions" segment growing 17% — the segment that would justify an EXLS-like 2.4x EV/Sales rerating. The single metric most likely to rerate or derate the stock is ATS revenue mix: every 300bps of mix shift toward ATS (at constant group margin) is worth roughly a full turn of EV/Sales if the market believes the mix durable. Secondary catalyst: new-bookings book-to-bill — FY25 bookings fell to $5.5B from $5.7B, which leads reported revenue by 3–4 quarters.

Price & Valuation Snapshot

The stock peaked at $50.26 on 2025-04-30 and touched a 52-week low of $34.18 on 2026-04-10 — a 32% peak-to-trough drawdown. Two air-pockets mark the narrative: the early-May 2025 gap from ~$49 to ~$42 (post-Q1 print / macro) and the February 2026 gap from $44 to $37 on the FY25 full-year print that missed consensus EPS ($3.13 vs $3.23E) despite 6.6% revenue growth.

Revenue & Earnings Power

The FY23 net income spike ($631M) is an artifact of a one-time ~$190M tax benefit. Adjusted, FY23 net income was ~$440M and the underlying earnings trajectory has compounded into FY25's $552M. FY23 is also where operating margin re-based ~250bps lower as wage inflation outpaced pricing — margins have held at 14.7–14.8% since but have not recovered to the FY22 peak. Sell-side models a gradual expansion back toward 15.2% by FY27.

Quarterly Trajectory

Revenue has grown every quarter from $1,089M (2023-Q1) to $1,319M (2025-Q4), a 21% two-year build. Margins traced a clean recovery through FY24 (13.3% to 15.2%) and then stopped expanding — the Q2/Q3/Q4 2025 prints of 14.3% / 14.8% / 14.8% are the problem for the bull case. That is why the FY25 EPS missed: it was a margin-expansion miss, not a top-line miss.

Earnings surprise (most recent print)

Cash Generation

FY25 free cash flow of $725M is a ~36% jump over FY24 and the highest absolute print in company history. Capex is trivial (~$78M, ~1.5% of revenue) — an asset-light services model where "investment" flows through the P&L as headcount. The cash quality is genuine: SBC is only ~$90M (1.8% of revenue), so SBC-adjusted FCF yield is still 10.2% — exceptional for a 7%-growth business. Net-income-to-FCF conversion of 131% reflects working-capital release and D&A > capex, and this is the single strongest pillar of the bull thesis that the price tape is ignoring.

Capital allocation — consistent return of capital

FY25 buybacks dropped to $97M from $235M in FY24 — cash instead funded the XponentL acquisition ($160M) and $314M of incremental net debt/investments. Dividend was raised 11.5% to $0.68/share (FY24: $0.61), yielding 1.9% at current price. Payout ratio is a disciplined ~21%.

Balance Sheet

Cash + short-term investments rose to $1.2B in FY25 (adding back $350M of current investments to $854M cash), while total debt rose to $1.93B reflecting new financing for XponentL and general balance-sheet optionality. Net debt/EBITDA is 0.86x — zero leverage stress. The company could comfortably fund a $500M–$1B incremental buyback or acquisition without credit-rating impact. Interest coverage is 10.9x.

Shares outstanding

Share count has fallen from ~185M to ~170M — the cleanest boost to per-share economics. At $36.65, every $100M of buyback retires ~2.7M shares.

Industry-Specific Metrics (Warren's scorecard)

Returns on Capital

ROIC stepped down sharply from 28.8% to 17.5% in FY25. The primary driver is mechanical — goodwill and intangibles grew to $1.85B (+9% YoY) on the XponentL transaction while earnings from that acquired business have not yet fully ramped. ROE held at 21.7% because buybacks shrank the equity base in step with net income. The question to monitor: does ROIC rebuild toward 20%+ by FY27 as ATS margins scale, or does it settle at ~15% indicating capital was mis-allocated?

Peer Comparison

Top Institutional Holders (partial)

What the Numbers Confirm, Contradict, and Demand

Confirm. The business is a cash machine: $725M FCF, 11.6% FCF yield, 0.86x net debt/EBITDA, ~$215M/year returned to shareholders via buybacks + dividends. ATS is accelerating (17% growth). Revenue has compounded cleanly to a record $5.1B.

Contradict. The narrative says "AI pivot real"; the FY25 margin trajectory (stalled at 14.8%) and the FY25 EPS miss ($3.13 vs $3.23E) say "not yet". ROIC stepped down to 17.5% from 28.8% — the XponentL deal has not yet earned its capital. Bookings fell $200M YoY — the leading indicator is soft.

Watch next quarter. (1) Q1-26 ATS growth print — must be >=15%; (2) Q1-26 gross margin — must expand YoY; (3) Q1-26 bookings — must grow QoQ; (4) any update on Agentic-solutions revenue disclosure. If any two of those four clear, the stock should reclaim $45. If three miss, expect a retest of the $34 April 2026 low.

Claude View

The People

Governance grade: A-. Genpact has institutional-quality governance — an 11-of-12 independent board, a separate independent Chair, 92% say-on-pay support, ~31% combined ownership by FMR/Vanguard/BlackRock, no dual-class shares, no poison pill, and a mandatory 6x-salary share ownership requirement for the CEO. The wart is a $6M off-cycle retention RSU granted to BK Kalra in December 2025 on top of his already-large package, and a 530:1 CEO pay ratio that is structurally high because most of the workforce is in India.

The People Running This Company

Balkrishan "BK" Kalra, President & CEO. Took over from N.V. Tyagarajan in February 2024 after joining Genpact in 1999 — originally as part of the GE Capital International Services team that became Genpact. No MBA, no marquee degree — a 26-year operator who ran the company's largest verticals (BFSI, Consumer Goods, Life Sciences) before the top job. Execution since promotion has been clean: 6.6% revenue growth, 17% growth in Advanced Technology Solutions, 11% adjusted EPS growth in 2025, and the company beat its own guide in each quarter. Beneficial ownership of 992k shares is mostly exercisable options (812k); direct shares are 181k.

Michael Weiner, CFO. Joined 2020 from Avis Budget Group where he was Treasurer and SVP Strategy. 91% of his target comp is at-risk, and his primary spend category is PSUs tied to the same 3-year revenue and adjusted-EPS goals as the CEO.

Piyush Mehta, CHRO and India Country Manager. A Genpact original from the GE days — longest-serving NEO with the largest beneficial stake (456k shares, incl. 368k options exercisable). India P&L ownership matters because ~95% of the 147k+ employee base is outside the U.S.

Anil Nanduru and Riju Vashisht, Business Leaders. Two of the three revenue-line owners. Both long-tenured. One related-party note: Anil Nanduru's sister-in-law Pallavi Nanduru is a VP in HR with compensation above $120k — disclosed, reviewed by audit committee, immaterial.

What to doubt. The board is entirely outsiders-plus-BK — there is no second operator on the board who could credibly push back on the CEO on operating details. The CEO's Dec-2025 $6M retention RSU suggests the board was worried about him leaving during the agentic pivot, which is unusual for a 26-year lifer.

What They Get Paid

Structure is right; absolute level is large. Kalra's $16.3M in 2025 sits above the non-CEO median S&P 400 IT-services peer but below Accenture/Cognizant. 91% of his target comp is at-risk (PSUs with 3-yr revenue + adjusted-EPS goals, plus rTSR modifier vs. S&P 400, and annual RSUs with graded vesting). 78% is long-term equity. PSUs measure the right things — revenue and adjusted EPS — with a relative TSR modifier to keep absolute share-price tailwinds from inflating payouts.

The friction point: Kalra's $6M one-time RSU. Granted Dec 2025, vesting one-third each Dec 2026/2027/2028, explicitly labeled a "retention" grant "to support Mr. Kalra's continued focus on driving the Company's strategic transition to agentic operations." The committee's rationale — that annualized $2M on top of ongoing comp brings Kalra closer to market median — is defensible, but a $6M retention award to a 26-year insider two years into the CEO role is the kind of thing proxy advisors flag.

Are They Aligned?

Ownership concentration is index-fund normal, with one notable long-term shareholder. FMR/Vanguard/BlackRock together hold ~31% — passive index exposure, not activist. The more interesting holder is Nalanda India Equity Fund (Pulak Prasad's Mauritius-domiciled long-only fund) at 7.74% — on file since a 2021 13G and visibly unmoved since. Nalanda is a known quality-compounder buyer; its patient presence at 7%+ is a credible external endorsement.

Insider activity is lopsided to the sell side, but it's the normal lopsided. Every open-market sale in the past 12 months was by someone simultaneously exercising options or cashing vested RSUs — classic post-vest monetization, not a signal. The one exception cuts the other way: director Nick Gangestad bought 2,000 shares on the open market at $43.97 in May 2025 — a small but real signal of confidence from the incoming audit chair.

The largest single sale — 108,880 shares at $54.87 ($5.97M, Feb 2025) — was the departing former CEO N.V. Tyagarajan after stepping off the board in May 2025. Expected, not alarming.

CEO behavior specifically. Kalra has sold 56,400 shares on the open market over 12 months for ~$2.5M. Same period: he received 337,647 shares in grants (including the Dec-2025 $6M retention RSU) and exercised 40,000 options. Net position has grown meaningfully. No programmatic 10b5-1 selling.

Skin-in-the-game: 7/10. Kalra's beneficial ownership of ~992k shares (of which 811k are exercisable options) is ~$36M at the current $36.65 price. That is 2.2x his 2025 total comp and ~40x his base salary — above the 6x requirement. But the bulk is option-heavy, not cash-paid common stock, which makes the alignment slightly cheaper than it reads. 7/10, not 9/10, because (a) most holdings are option-based, not paid-in, (b) the top-5 NEO group is only 1.58% of shares, and (c) the December 2025 retention grant reads as a concession to a CEO with a reasonable — not extraordinary — tolerance for staying.

Capital allocation discipline: strong. In 2025 Genpact returned $401M to shareholders: $283M in buybacks (6M shares at an average $46.16) plus $118M in dividends. Dividend was raised 10% to $0.75/share annualized for 2026. They bought shares at an average price ($46.16) visibly above the current quote ($36.65), which is a minor blemish on timing, but the repurchase pace is sustained and material relative to a $6.2B market cap.

Related-party: trivial. Only disclosed RPT in 2025 is that Anil Nanduru's sister-in-law is a VP in HR earning >$120k. Reviewed and approved by the audit committee. Everything else normal.

Board Quality

The basics are right. 11 of 12 are independent; only Kalra is not. Chair (Madden) and CEO are separate — and Madden has held the chair role as an independent for years, which is the structure serious governance investors want. All three committees are 100% independent. Two audit committee financial experts (Verdi and Gangestad) — Gangestad, a former 3M CFO, is taking over the audit chair in 2026. That's a real upgrade.

Skills coverage — with one gap. The director skills matrix shows 10/10 with senior leadership experience, 10/10 with finance/risk, and 8/10 with innovation/technology. The weakest area is specific AI/agentic-operations expertise on the board itself; the company has delegated AI oversight to the Nominating & Governance Committee starting 2026 and pulls from a management-led Responsible AI Committee. Given that "GenpactNext" is an agentic-AI bet-the-company pivot, the board should arguably add a sitting AI operator in the next refresh cycle. Thimaya Subaiya (ex-Cisco CX, Salesforce) and John Hinshaw (ex-HSBC Group COO, HP EVP) partially fill this — but neither is an AI specialist.

Refreshment is active. Two directors (Agrawal, Franklin) are not standing for re-election in 2026. Four have joined in 2024-2025 (Kalra, Gangestad, Hinshaw, Subaiya). Median tenure 7.8 years. Longest-serving is Madden at 20+. The board is turning over at a steady, not disruptive, pace.

Meeting engagement is adequate. 8 board meetings in 2025 with 92% average attendance; 100% attendance at the 2025 annual meeting by sitting directors. Audit committee met 14 times — unusually active, which is a positive signal given Genpact's cross-border tax exposure and India footprint.

The Verdict

Grade: A-.

Strongest positives.

Independent Chair and 11/12 independent board — the structural basics are all done right.

91% of CEO pay is at-risk, tied to 3-year revenue, adjusted EPS, and relative TSR vs. S&P 400.

92% say-on-pay support in 2025; extensive shareholder engagement led to concrete changes in 2023 (eliminated time-based options, added 3-yr PSU performance period, added rTSR modifier).

Pulak Prasad's Nalanda at 7.7% for 5+ years is the most credible external endorsement you get without an activist.

CEO Kalra is a 26-year lifer, not a parachute hire — institutional knowledge plus clean post-promotion execution.

No poison pill, one share/one vote, anti-hedging/anti-pledging enforced, clawback active.

Real concerns.

The $6M one-time retention RSU to a 26-year lifer two years into the CEO role is defensible on "market median" math but feels like a tell that the board needed to lock Kalra in.

530:1 CEO pay ratio is structural (95% India workforce) but optically hostile.

No sitting AI/agentic operator on the board even though GenpactNext is an agentic pivot.

Directors + officers own only 1.58% of shares — there is no material inside ownership, only compensation-driven alignment.

What would move the grade.

Upgrade to A if Kalra meets the 6x base salary requirement in directly-held (not option) shares and the 2026 proxy shows Nalanda adding or a named AI operator joining the board.

Downgrade to B+ if the 2026 annual RSU awards include another off-cycle special grant, or if say-on-pay drops below 85% (the 2022-2023 compensation-committee changes were the direct response to a prior vote closer to the 85% threshold, so the governance machine has shown it reacts).

Claude View

The Full Story

Genpact's three-year narrative under new CEO BK Kalra (Feb 2024–present) is a rerun of the same slide, sharpened each quarter: the firm is no longer selling "labor-arbitrage BPO" — it is selling Data-Tech-AI and, since mid-2025, Agentic Operations riding on top of a stable, high-retention Digital Operations base. The quiet truth underneath the slide is that growth sits squarely inside Data-Tech-AI (and, within that, the new Advanced Technology Solutions reporting segment, up 17% in 2025), while the 75%+ of revenue in Core Business Services compounds at ~3–4%. Credibility on financial guidance has clearly improved — Kalra beat-and-raised in five of his first six full quarters and closed 2025 exactly where the mid-year bar sat. The open question the 2025 10-K hints at, but management has not yet confronted head-on: new bookings fell from $5.7B in 2024 to $5.5B in 2025, even as reported revenue growth accelerated.

1. The Narrative Arc

Eight quarters of earnings releases describe three distinct chapters, each anchored by a management "framework" that gets renamed roughly once a year. The chart below marks the inflection points.

What changed. Three things, not just the CEO. First, the company tagline was rewritten twice in 24 months — from "global professional services and solutions firm delivering outcomes that shape the future" (Q1'24) to "global advanced technology services and solutions company" (Q4'24) to, by late 2025, "an agentic and advanced technology solutions company recognized for its deep industry knowledge, process intelligence, and last-mile expertise." Second, the segment grouping changed mid-2024 and again in mid-2025: Digital Operations / Data-Tech-AI was reclassified (shifting ~$100M of 2023 revenue from Digital Ops into DTA) and then a parallel "Advanced Technology Solutions / Core Business Services" view was added. Third, the strategic buzzword turned over: the "3+1 Execution Framework" (Q1'24) is gone by mid-2025, replaced by "GenpactNext" and "Agentic Operations." None of these are scandals — they are evidence that Kalra is deliberately re-positioning Genpact from a BPM peer (vs. WNS/EXLS) toward a tech-services peer (vs. CTSH/ACN), where multiples are higher.

2. What Management Emphasized — and Then Stopped Emphasizing

The table below tracks how often each theme appeared in the eight prepared-remarks headlines. Intensity is coded 0 (absent) to 3 (headline-level emphasis) based on explicit mentions in the press-release lead paragraphs and CEO quotes.

Three things stand out. The "3+1 Execution Framework" was the rhetorical spine of Kalra's first three quarters and then vanished — the phrase does not appear in any 2025 release. That is a classic operator's pivot: the framework served its purpose (it was Kalra's way of staking out his identity against ex-CEO Tyagarajan), and once the new segmentation and GenpactNext narrative took over, the scaffolding was discarded. Agentic solutions went from absent (all of 2024 through Q3) to headline concept in three quarters. And new bookings, which management proudly crowed about at Q4'24 ("record $5.7B, up 15%"), were silently dropped as a headline metric the moment the number went the other way — Q4'25 disclosed only adjusted EPS, buyback, and dividend; the $5.5B 2025 bookings figure appears only in the 10-K MD&A.

3. Risk Evolution

Risk-factor language across the FY2023–FY2025 10-Ks shifts in a specific direction: more AI, more client concentration risk, more cyber, plus a brand-new tariff/trade category. Intensity below reflects the depth and prominence of the disclosure, not merely presence.

New in FY2025: tariffs / US trade policy appears for the first time as a standalone risk — a direct response to the Q1'25 guidance cut. Elevated in FY2025: agentic AI is now a named technology category, and the "clients may develop their own AI capabilities" language is explicit enough to read as an acknowledgement of disintermediation risk. De-emphasized in FY2025: the CEO-transition risk that dominated FY2024 has been largely dropped — Kalra is now incumbent. Notably, Digital Operations pricing pressure did not ease; management continues to warn it may not be able to pass cost inflation to clients on legacy long-tenured contracts.

4. How They Handled Bad News

Two episodes in the eight-quarter window matter: the Q1 2025 tariff-driven guide-down and the quiet 2025 bookings decline. Management's handling differs sharply.

Episode 1: Q1 2025 guidance cut (April 2025)

Between the February-2025 Q4'24 call (guiding FY25 revenue 5.5–7.5%) and the May-2025 Q1'25 call, the FY25 revenue guide was slashed to 2.0–5.0% — a ~3-point midpoint cut — on the back of tariff-driven client caution. Management's response was direct but careful: the word "tariff" never appears in the Q1'25 press release; instead Kalra said only that "the operating environment has changed since the beginning of the year." By Q2'25 the guide was raised back to 4.0–6.0%, by Q3'25 to 6.1–6.4%, and by Q4'25 actual delivery landed at 6.6%. The cut was real and quickly walked back — credibility net-neutral because the recovery was fast, but the absence of the word "tariff" in a quarter when the whole services sector was talking about tariffs looks rehearsed.

Episode 2: 2025 bookings decline (disclosed Feb 2026)

The 2024 bookings "record" was a headline; the 2025 bookings decline was a footnote. The Q4'25 press release devotes zero sentences to bookings. The 10-K, filed three weeks later, discloses that FY25 new bookings were $5.5B vs. $5.7B in FY24 — down ~3.5% in absolute terms (and by more if one adjusts for the 2024 re-definition that lifted prior-year bookings by ~$300M of multi-year contract value).

5. Guidance Track Record

The beat-and-raise cadence under Kalra has been strong — four consecutive full-year guidance raises in 2024, four in 2025. Every quarterly print since Q2'24 has been above the high end of the previous quarter's range.

Scorecard. FY2024 actual ($4.767B) came in modestly above the post-Q3 range ($4.740–4.751B) — classic under-promise, over-deliver. FY2025 actual ($5.080B) was inside the initial Feb-2025 range but required a mid-year detour through a lower range after the tariff shock. Adjusted-EPS guidance was raised every quarter in both years. On capital return, management delivered: two dividend raises (11% in 2024, 10% in 2025), two buyback authorizations (+$500M in Feb 2025), and $535M of share repurchases over the two years.

8 of 10. Kalra inherited a BPM business that was growing 2% and has it growing ~7% with margins up ~70 bps and EPS growing 11–16% quarter after quarter. The financial commitments have been met. The deduction is for the two pieces of disclosure discipline that slipped: (a) the 2025 bookings number quietly moved off the press release and (b) the "3+1 Framework" was retired without any post-mortem on whether it worked. Neither is fatal, but both are the kind of pattern that, compounded over another 18 months, would start to matter.

6. What the Story Is Now

The current Genpact story, cleaned up:

What management is selling. "We are the last-mile operator for enterprise AI. Clients already trust us with their revenue-cycle, finance-and-accounting and supply-chain operations. As they deploy generative and agentic AI on top of those workflows, we are the natural integration partner — and we price these new offerings on outcomes, not headcount." The fast-growing piece of this story (Advanced Technology Solutions, ~24% of revenue, growing 17%) is growing 4–5× the rate of Core Business Services (~76% of revenue, growing 3–4%). The 2026 plan (≥7% revenue growth, +25 bps adj. margin, ~10% adj. EPS growth) is an extension of the 2025 print, not a step-up.

What has been de-risked. CEO transition — Kalra is now two years in and has a track record. Margin trajectory — four years in a row of adj-EPS growing faster than revenue. Capital return — dividend and buyback cadence are reliable. The legacy reclassification noise in segment reporting has washed through.

What is still stretched. (1) The thesis assumes ATS compounds at least 15% for the next several years; one quarter of ATS deceleration collapses the growth story because CBS is low-single-digit. (2) Bookings. A services firm whose bookings are declining while revenue is accelerating either has excellent revenue conversion or is pulling forward backlog — both explanations need to be addressed on the Q1'26 call. (3) The top line is still 76% dependent on a book of business that looks a lot like what competitors offer — the AI "last-mile" differentiator is marketing language today; it becomes an investable moat only if CBS retention and pricing hold while the AI content inside CBS grows.

What the reader should believe. The financial execution is real, the quarterly guidance discipline is real, and the Data-Tech-AI growth is real. What the reader should discount. The every-six-month rebranding ("3+1" → "GenpactNext" → "Agentic Operations"), the absence of a hard KPI for "how much revenue is actually AI-monetized" (vs. just sitting in the DTA segment), and the silence on the 2025 bookings decline. This is a company that has cleaned up its execution story but not yet its disclosure habits — a ~7% grower with cleaning-up-is-still-happening credibility, priced at ~12× earnings.

Claude View

What's Next

The window that matters is narrow. Today is April 17, 2026. Genpact historically reports Q1 in the first week of May (Q1'25 dropped May 1); the Q1'26 call is the first test of whether management re-opens the bookings conversation after quietly dropping a $200M YoY decline into the 10-K footnotes. The stock has round-tripped from $50 (April 2025) to a fresh 52-week low of $34.18 on April 10, 2026 — a 32% drawdown into the print. What the market is actually asking is narrow: is ATS still compounding at 17%+, or has the AI pivot already decelerated before it crossed 30% of revenue?

Sell-side estimates for FY26 sit at $5.43B revenue (6.8% growth) and $3.59 EPS (14.7% growth) — a modest step-up from FY25's 6.6% / 11% actuals. At $36.65, the stock is priced as if ATS decelerates to low-teens and margins stall, which is a low bar that management has cleared every quarter under Kalra. The catalyst isn't exotic; it's a clean Q1 print with bookings back on the headline and ATS at 17%+.

For / Against / My View

For

Against

My View

Close call, slight edge to the bulls at this price — but it is the price doing the work, not the fundamentals. At $36.65 with 11.6% FCF yield, a 10x forward P/E, Nalanda sitting patient, and Kalra having rebuilt guidance credibility, I'd lean cautiously long into the Q1'26 print, but with the understanding that this is a mispricing trade (close the peer gap to EXLS) rather than a secular compounder story. The item that tips the scale: Quant's chart of G at 1.44x EV/Sales vs EXLS at 2.43x with faster growth is not explainable by fundamentals alone — it is explainable by skepticism about ATS durability, and that skepticism has a testable expiration date in two weeks. What would flip me to the Against side: any Q1 print that shows ATS below 15% growth, or a second consecutive year of bookings decline disclosed on the call rather than buried in the K. That single data point makes Warren's giveback math the dominant read and resets the multiple lower — there is no version of this thesis where you own a 10x stock whose forward growth rate is actually 4%.

Claude View

Web Research: What the Internet Knows About Genpact

The Bottom Line from the Web

The web paints a far darker near-term picture than the filings alone suggest — but also delivers one large, unambiguously bullish anchor. Genpact traded at a 52-week low of $33.92 on April 10, 2026 — days before this report — and sits near $36.63 versus a May-2025 high of $50.41, a drawdown of roughly 27% in under a year. Susquehanna cut the price target from $50 to $42 right after the Q4-2025 print, and a second analyst downgrade in February 2026 drove the stock to new lows. Meanwhile, Capgemini closed its $3.3B acquisition of WNS at $76.50/share on October 17, 2025 — an unambiguous transaction-anchored peer comp that the market has not yet applied to Genpact — and Nalanda Capital added roughly 1 million shares in February 2026 into the weakness, raising its stake to ~8.07%.

What Matters Most

The eleven findings below are ranked by how much they should move an investor's view of the stock today.

1. Capgemini/WNS deal closed Oct 17, 2025 at $3.3B — sets the BPM transaction multiple

Capgemini completed its $3.3B cash acquisition of WNS at $76.50/share on October 17, 2025, a 28% premium to the 90-day average and 17% to WNS's pre-announcement close (capgemini.com, everestgrp.com, reuters.com). This is the single most important peer datapoint on the web: it confirms that a strategic acquirer will pay ~2.9x EV/Sales for a pure-play BPM franchise pivoting to agentic AI. Against Genpact's current ~1.4x EV/Sales (implied by $6.2B market cap + ~$1.2B net debt on $5.1B revenue), the comp suggests the stock trades at a ~50% discount to the most recent strategic transaction in the space.

2. Stock at 52-week low despite raised guidance — the market is pricing disbelief

Shares closed $36.63 on April 16, 2026 (CNBC), after hitting a 52-week low of $33.92 on April 10, 2026 — yet Q2-2025 revenue beat consensus (+6.6% YoY), ATS grew +17.3%, and management raised FY25 revenue guidance to +5% at midpoint (media.genpact.com, 2025-08-07). Q3-2025 then delivered another beat with ATS up 20% YoY (prnewswire.com, 2025-11-06). Forward P/E has compressed to 9.1x (CNBC) vs. the market's high-teens and EXLS's 30x+. This is the single most important contradiction between filings and tape — the AI-pivot story is not earning a multiple.

3. Nalanda Capital added ~1M shares in Feb-2026 — anchor investor doubling down

Pulak Prasad's Nalanda Capital filed its most recent 13F on February 18, 2026 (period ending Dec 31, 2025) showing Genpact as its top US holding, and The Motley Fool confirmed on Feb 20, 2026 that the fund added roughly a million shares into the post-earnings sell-off (fool.com, 2026-02-20; whalewisdom). Nalanda is known for concentrated, long-duration, "buy companies you don't need to sell" positions — the fund manages ~$5B for US endowments and European family offices and holds only two US positions (Genpact and WNS). The WNS position is now realized cash (Capgemini deal) — freeing capital that could be redeployed into G.

4. Susquehanna cut price target $50 → $42 on Feb 6, 2026 — framing the re-rating

Within hours of the Q4-2025 earnings release on Feb 6, 2026, Susquehanna reduced its G price target to $42 from $50 (TipRanks via CNBC). A separate analyst downgrade on Feb 11, 2026 drove the stock to fresh 52-week lows per Defense World and Markets Daily (Mizuho cut target to $49 from $51). BMO's Keith Bachman cut his target to $44 from $48, maintaining Market Perform. Baird had earlier cut $56 → $50 on May 10, 2025. The proximate bear thesis per TipRanks ("conflicting sentiments on technology companies," Feb 9, 2026): sell-side views Genpact's AI pivot as slower and more capital-intensive than EXLS's. Consensus 12-month target remains ~$51–$52 (indmoney.com, marketscreener).

5. Executive team expansion signals GenpactNext is real (not just a rebrand)

On Dec 10, 2025, Genpact announced three senior appointments explicitly to "fuel integration of Advanced Technology Solutions": Vijay Vijayasankar (leading Industry + GenpactNext delivery), Wayne Busch (Head of NextGen Enterprises P/L), and Sydney Brie Schaub (Chief Legal Officer) — prnewswire.com. CEO BK Kalra framed it: "We are intentionally disrupting ourselves, building a new Genpact and defining the future of Agentic Operations." Adding a dedicated "NextGen Enterprises" P/L leader answers the Historian's question about whether GenpactNext is a product change or a marketing rebrand — the org-chart move says the former.

6. Board refresh — Cisco EVP Thimaya Subaiya added July 2025

Subaiya joined the board on July 31, 2025 from Cisco, where he runs a $13B services P/L as EVP of Operations; prior career at Salesforce and Oracle (prnewswire.com). Chairman Jim Madden framed the appointment as "supporting the leadership team in advancing the GenpactNext framework." This is a meaningful governance signal — the board is skewing toward software/services-transformation expertise rather than traditional BPM.

7. XponentL Data acquisition closed June 5, 2025 — capability fill, not scale

Genpact acquired XponentL Data (Databricks partner, AI/data products, PA-headquartered) on June 5, 2025 — financial terms were not disclosed in the press release (prnewswire.com). Quant's research notes that the deal dragged ROIC from 28.8% to 17.5%, pointing to a ~$160M price tag. CEO Tom Johnstone stays on to run the XponentL business inside Genpact. No web-sourced segment contribution has been disclosed — the capital-return question remains open.

8. Bookings in 2025 dipped to $5.5B from $5.7B — no explicit explanation

FY2024 posted record new bookings of $5.7B, +15% YoY (prnewswire.com, 2025-02-06). FY2025 bookings were publicly cited as "over $5.5B" (businesswire.com, 2026-02-05), down ~3.5% YoY despite record backlog commentary. Notably, ATS represented more than a third of FY25 bookings. The Q4-2025 press release leaned entirely on "record backlog" language rather than the bookings number — the silence on the decline is itself a signal. Management claims backlog is at record levels, but no detailed bridge was provided.

9. November 2025 post-earnings gain of ~16% shows earnings still move the stock both ways

A Nov 7, 2025 Motley Fool piece titled "Why Genpact Stock Raced Nearly 16% Higher Today" documents the Q3-2025 beat reaction (fool.com). Combined with the subsequent Feb 2026 downgrades, this demonstrates a binary, event-driven market — the stock is not being valued as a stable compounder. Expectations reset sharply on every print, which creates both risk and asymmetric set-ups around upcoming earnings (next date: May 7, 2026 per CNBC).

10. Dividend raised for 8 consecutive years — capital return story intact

Annual dividend is $0.75/share, yielding 2.05%, with 8 consecutive years of growth and an 11.48% 1-year growth rate; payout ratio a conservative 21%. Q2-2025 alone returned $54.8M in dividends + $30M in buybacks; Q1-2025 repurchased 1.2M shares at an average $52.17 — above today's $36.63 price, meaning recent buybacks have been poorly timed (media.genpact.com, 2025-05-07).

11. ISS Governance QualityScore = 1 (best decile)

ISS's overall QualityScore for Genpact as of February 1, 2026 is 1 (Audit 1; Board 1; Shareholder Rights 3; Compensation 2) — simplywall.st. No proxy-advisor opposition coverage surfaced for Kalra's 2025 compensation package or any off-cycle retention grant. No SEC investigation, restatement, or material-weakness coverage appeared in the web pull.

---

Recent News Timeline

---

What the Specialists Asked

The four specialists submitted targeted queries with "high" priority answers anchoring the tabs below.

---

Insider Spotlight

Web research on individual insiders was consistent with a clean governance profile — no scandals, no adverse regulatory coverage, no forced departures. Key personnel snapshot below.

Source: marketscreener.com/quote/stock/GENPACT-LIMITED-57248/company + whalewisdom 13F (filed 2026-02-18). Nalanda increased by ~1M shares in Feb 2026 per fool.com; stake now ~8.07%, #4 holder.

---

Industry Context

BPM/IT-Services peer framing from the web search, focused on the two datapoints that matter most for G's multiple: EXLS premium and the WNS transaction anchor.

Sources: CNBC (G TTM/fwd PE), Nasdaq/Zacks (EXLS), Capgemini/Reuters/Everest Group (WNS deal), stockanalysis.com (ACN). EV/Sales for WNS = deal price 2.9x; current G implied from $6.2B market cap + ~$1.2B net debt / $5.1B revenue.

Key industry findings from the web:

• Strategic acquirer has set a concrete floor. Capgemini paid 2.9x EV/Sales for WNS in Oct 2025 — a 28% premium to WNS's 90-day average. Genpact trades at ~1.4x EV/Sales, implying ~100% deal-multiple upside to the most recent strategic transaction.
• Agentic-AI displacement risk is concrete, not theoretical. CNBC's Mar 19, 2026 headline about Meta "cutting third-party vendors in favor of AI" appeared in G's own CNBC news rail. Everest Group explicitly framed the Capgemini-WNS deal as "renewed BPS positioning in an AI-first world" — confirming the structural threat driving the multiple compression.
• Peer valuation gap is the investable thesis. G at 9.1x forward vs. EXLS >28x suggests either (a) a closing opportunity if ATS sustains >15% growth, or (b) a value-trap if agentic disintermediation accelerates faster than Genpact can pivot.
• Capital-return discipline intact. 8 consecutive years of dividend growth (+11.5% last year, koyfin.com) and an active buyback (Q1-2025: 1.2M shares at $52.17 avg, Q2-2025: $30M). The $52.17 avg buyback price is now 30% underwater — a bad trade tactically, but a real signal of management conviction.
• Credit is fine. Long-term debt $1.2B against $855M TTM EBITDA; Debt/Equity 61.25% (CNBC). November 2025 pricing of 4.950% Senior Notes due 2030 by Genpact UK Finco/Genpact USA (sec.gov) — credit markets remain open at tight spreads.